Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review evaluates the clinical experience of using low-dose oral minoxidil for treating alopecia and highlights the ongoing concerns about its potential side effects without reporting new clinical results.

Low-dose oral minoxidil is safe for treating hair loss, especially in women, with side effects stopping after use ends.

This study evaluated low dose oral minoxidil as a treatment for female pattern hair loss but reports no new clinical results.

This study reported that low dose oral minoxidil may help treat persistent chemotherapy-induced alopecia, based on a retrospective case series involving 15 patients across multiple centers.

This expert consensus discusses the potential use of oral minoxidil for treating alopecia and provides guidance to clinicians based on a comprehensive literature review and expert feedback; it reports no new clinical results.

This study of South Indian patients with autoimmune rheumatic diseases using low-dose methotrexate reported that while mild adverse effects such as hair loss and nausea were common, serious events like cytopenia were less frequent, and folic acid supplementation significantly reduced their prevalence.

This review discusses the potential of low-dose oral minoxidil as a safe and effective treatment for certain hair disorders, including alopecia, but reports no new clinical results.

This letter highlights the lack of evidence on managing persistent alopecia induced by chemotherapy and endocrine therapy in breast cancer patients, noting that prior studies have not included endocrine therapy-induced alopecia.

This study found that Ageratum conyzoides showed antihyperglycemic and antilipidemic effects in diabetic rats, with significant changes in hematological and serum electrolyte parameters at 2000mg/kg.

High-dose corticosteroids can significantly regrow hair in severe alopecia areata.

This study illustrates that low-dose oral minoxidil shows clinically notable hair regrowth, particularly at the crown in male patients, with differing efficacy from bitemporal sites; images document regrowth in a male and a female patient.

This study found that using rind-based dosimetric techniques in brain irradiation significantly reduced scalp dose and alopecia compared to standard treatment plans, with 60% of patients experiencing no hair loss.

This study observed that intravenous ferric carboxymaltose did not inhibit the drug-induced reduction of inflammatory activity in patients with inflammatory bowel disease, as indicated by lower CRP levels.

This study presents an algorithm that may help physicians diagnose female hair loss by synthesizing patient history, clinical examination, and various diagnostic tests.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

Low-dose finasteride lowers PSA levels, which can make prostate cancer harder to detect.

There is no abstract available for this article on the effects of percutaneous oestradiol implants on the skeletons of postmenopausal women, and thus no new findings are reported.

This study found that 29.4% of patients treated with methotrexate for non-hair-related conditions experienced increased hair loss, with more frequent reports among women.

High doses of progesterone can reduce seizures in mice.

This case report describes successful treatment with low-dose oral minoxidil for endocrine therapy-induced alopecia in a breast cancer patient unresponsive to topical minoxidil.

This publication discusses the use of low-dose oral minoxidil for treating traction alopecia but reports no new clinical outcomes; further research on its efficacy and safety is needed.

This review highlights emerging evidence that low-dose oral minoxidil could be used off-label to treat androgenetic alopecia, offering insights into its potential mechanisms and clinical applications beyond its current role in treating hypertension.

Low-dose oral minoxidil is a promising, safe treatment for various hair diseases, improving hair thickness and density, but more research is needed on long-term side effects and treatment duration.

This study evaluates the use of 5 mg/day finasteride for treating patterned hair loss in normo-androgenetic postmenopausal women, although results are not included in the abstract.

This study found that spironolactone reduced serum androstenedione and anagen hair shaft diameter in hirsute patients but did not significantly alter unbound testosterone levels, suggesting its effects are primarily peripheral.

This study found that combining low-dose spironolactone with metformin provided greater clinical benefits and improved treatment compliance in women with PCOS compared to either drug alone.

This study found a strong dose-related increase in the risk of intracranial meningiomas associated with high doses of cyproterone acetate, with some reduction in risk after stopping the treatment.